


Our Advantage is our
Commitment to Excellence



OCT GROUP

Full-service clinical trials in Central and Eastern Europe

OCT presence in CEE



OCT Offices

 **OCT GROUP**
Full-service clinical trials in Central and Eastern Europe

Riga

 **OCT GROUP**
Full-service clinical trials in Central and Eastern Europe

Sofia

 **OCT GROUP**
Full-service clinical trials in Central and Eastern Europe

Minsk

 **OCT GROUP**
Full-service clinical trials in Central and Eastern Europe

New York

 **OCT GROUP**
Full-service clinical trials in Central and Eastern Europe


St. Petersburg

 **OCT GROUP**
Full-service clinical trials in Central and Eastern Europe

Moscow

 **OCT GROUP**
Full-service clinical trials in Central and Eastern Europe

Kiev



Organization Chart


OCT infrastructure in Russia




Clinical Staff



OCT Staff more than 85 people in total



90 % of CRAs and PMs are medical doctors



1/2 of the staff are in clinical department

Clinical Experience

Therapeutic Area	Indication	Phase
2006		
Oncology	Immunotherapy in Renal Cell Carcinoma	Phase III
Oncology	T-cell Leukemia	Phase II b
Nutrition/Pediatrics	Prevention of common infectious disease	Phase III–IV
Dermatology	Acne	Phase II–III
Cardiology	Acute Heart Failure	Phase III
2007		
Oncology	Breast Cancer	Phase II
Gastroenterology	Crohns disease	Phase II
Oncology	Prostate Cancer	Phase II–III
Oncology	Breast cancer	Phase II
Cardiology	Acute Myocardial Infarction + LVH	Phase IV
Gastroenterology	Irritable Bowel Syndrome	Phase III
Oncology	Breast Cancer, neutropenia	Phase III
2008		
Oncology	Bone metastases, pain	Phase II
Ophthalmology	Age-related macular degeneration	Phase I

Clinical Experience

Therapeutic Area	Indication	Phase
2008		
Oncology	Prostate cancer	Phase III
Neurology	Brain vessel aneurysm rupture	Phase III
Endocrinology	Diabetes Mellitus	Phase II
Oncology	Ovarian Cancer	Phase III
Autoimmune disorders	Rheumatoid arthritis	Phase II
Oncology	Breast Cancer	Phase III
Oncology	Solid tumors	Phase I
2009		
Gastroenterology	H. Pylori	Phase II
Endocrinology	Hypothyriosis	Phase IV, register
Gastroenterology	Liver diseases	Post-marketing
Endocrinology	Diabetes Mellitus	Phase II
Urology	Erectile Dysfunction	Phase III
Oncology	Breast cancer	Phase II
Cardiology	Hypertension+LVH	Phase IV
Hepatology	Hepatic cirrhosis	Phase III

Clinical Experience

Therapeutic Area	Indication	Phase
2010		
Oncology	Advanced cancer/solid tumor	Phase I-IIa
Surgery	Pain	Phase II
Pediatrics Gastroenterology, Neonatology	Flatulence, intestinal colics	IV, register
Oncology	Metastatic breast cancer	Phase II
Cardiology	Hypertension	Phase II
Neurosurgery	Aneurism rupture	Phase III
CNS	Bioequivalence	BE/PK
Endocrinology	Autoimmune thyroiditis	Phase IV
Oncology	Cancer	Pre-clinical
Neurology	Multiple Sclerosis	Phase IV, register
Oncology	Colorectal cancer	Phase III
Oncology	Endometrial cancer	Pre-clinical
Oncology	Solid tumors	Phase II

Clinical Experience

Therapeutic Area	Indication	Phase
2010		
Gastroenterology	Liver disorder	Phase IV, register
Traumatology, orthopedics	Major joints surgery	Phase III
Pulmonology, Pediatrics	Bronchitis, pneumonia, asthma	Phase IV, register
Respiratory	Sore throat associated with URTI	Phase II
Oncology	Ovarian cancer	Phase III
Oncology	Metastatic breast cancer	Phase II
Otorinolaringology	Rhinitis	Phase IV, register
Oncology	Endometrial cancer	Phase II-III
Surgery	Colorectal anastomosis	Pilot (device)
Pediatrics	Acute bronchitis	Phase IV
Systemic diseases	Mastocytosis	Phase II
Pediatric/gastroenterology	Intestinal colics	Phase II
Infectious diseases	HDV	Phase I
Oncology	Colorectal cancer	Phase II

Clinical Experience

Therapeutic Area	Indication	Phase
2011		
Poisoning	Sedation of benzodiazines	Phase III
CNS	Healthy volunteers	BE
Oncology	Multiple myeloma	Phase III
CNS	Multiple sclerosis	Phase I
Oncology	Breast Cancer	Phase I-II
Oncology	Cancer	Pre-clinical
Cardiology	Hypertension	Phase III
Psychiatry	Alcohol addiction	Phase I in healthy volunteers
Surgery	Ischemic foot ulcers	Phase III
Oncology	Solid tumors	Phase I-II
CNS	Hemispheric ischemic stroke	Phase IV
Otolaryngology	Stable angina	Phase IV
Oncology	Cancer	Pre-clinical

Clinical Experience

Therapeutic Area	Indication	Phase
2011		
Oncology	Locally Advanced Pancreatic Adenocarcinoma	Phase II
Internal diseases	Chronic fatigue	Phase I in healthy volunteers
Oncology	Colorectal cancer	Phase III
Oncology	Bladder cancer	Phase II
Respiratory diseases	Asthma, COPD	Phase III
Oncology	Head and neck cancer	Phase III
Therapy	Arthrosis, Polyarthritis	BE
Cardiology	Isolated systolic hypertension	Phase III
Pediatrics	Colitis	Phase II
Oncology	Advanced solid tumors	Phase I b
Therapy	Myalgia, arthritis	Phase III
Pulmonology	Bronchitis, Pneumonia	BE
Rheumatology	Gout	Phase III
General medicine	Wound healing	Phase II; device

Clinical Experience

Therapeutic Area	Indication	Phase
2011		
Gastroenterology	Spasms, colonoscopy	Phase III
Therapy	Central catheter's maintenance	Phase II
Surgery	Parenteral nutrition	Phase III
Rheumatology	Rheumatoid arthritis, psoriasis	Phase IIb-III
Poisoning	Healthy volunteers	Phase I
Oncology	Neutropenia in breast cancer	Phase I-II
Neurology	Pregnancy registry, multiple sclerosis	Post-marketing
Pain	Healthy volunteers	Phase I
Urology	Benign prostatic hyperplasia	BE
Oncology	Solid tumors	Phase I
Virology	Healthy volunteers	Phase I
Gynaecology	Mastalgia	Phase III (registration)

Clinical Experience

Therapeutic Area	Indication	Phase
2012		
Neurology	Multiple sclerosis	Bioequivalence
Oncology	Prostate Cancer	Bioequivalence
Oncology	AML	IIa
Infectious disease	HBV	IIa
Pediatrics	Pain and inflammation	BE
Oncology	Neutropenia	IIb
Oncology	Solid tumors	Pre-clinical
Pain	Pain and inflammation	BE
Consultancy	Development of a regulatory strategy	Consultancy
Consultancy	Interpretation of guidelines	Consultancy
Oncology	Advanced melanoma	I
Cardiology	Coronary artery disease	IV
Respiratory	Sore throat	III

Clinical Experience

Therapeutic Area	Indication	Phase
2012		
Oncology	Breast cancer	II
Cardiology	Non-valvular atrial fibrillation	IV
GCP Training	GCP Training	GCP Training
Oncology	Head and neck cancer	Medical writing
Otolaryngology	Sore throat	III
Neurology	Vascular dementia	Medical writing, consultancy
Therapy	Pain	III
Medical Writing Training	Medical Writing Training	Medical Writing Training
Cardiology	Atherosclerosis	I-II
NSAID / Ophthalmology	Postoperative ocular inflammation / pain	III
NASID / Rheumatology	Arthritis / pain	Bioequivalence

Services provided by OCT

- Consulting
- Medical writing
- Feasibility assessment
- Project management
- Regulatory support
- Clinical monitoring
- CRA training
- Logistics support
- Quality assurance, Audits
- Purchase of concomitant medication
- Data management
- Statistics
- Safety Management



Clinical trials **HOW WE DO IT**

Consulting and Medical Writing

- Consulting and Medical Writing
- Study design in country-specific environment
- Sample size calculation
- Development of study essential documents
- Study protocol
- Informed Consent Form
- Investigators' Brochure
- IMPD review
- Strategic clinical development planning

Project Management

- Primary client contact and every-day communication
- Project planning
- Ensuring strict adherence to project timelines, budget, and quality performance in accordance with CFR 21/ICH GCP and local regulations
- Team trainings
- Principal Investigator selection
- Investigators' Meeting preparation

Assuring quality of monitoring


- Medical Doctors on staff
- Monitors have at least 2 years of experience
- Accumulated experience in all therapeutic areas
- Team trainings
- Second person review of monitoring reports
- Internal audits
- Site selection based on experience
- Co-monitoring
- Project review meetings

Regulatory support

- Translation (when applicable) of essential study documents required for submission
- Adjustment of informed consent forms to country-specific requirements, cultural adaptation
- Collection of documents required for submission from investigators
- Arrangement of local insurance
- IMPD preparation if required
- Preparation and QC of the submission application
- Submission of the clinical trial application to regulatory authorities and ethics bodies
- Communication with regulatory authorities and ethics bodies if required
- Export / import license

Regulatory approval timelines

Average time from application submission
to final study approval (days)



Logistics support

- Import of drugs, laboratory kits, other supplies
- Export of biologic samples
- Customs clearance
- Shipments tracking
- Clinical trial materials distribution to sites
- Collection of biologic samples from sites
- Biosample export to central laboratories

DM and Biostatistics

- EDC System development (CDISC CDASH compliance)
- Double data entry (for paper CRF)
- Clinical trial database creation and maintaining
- Data cleaning and query processing
- Data coding (acc. to MedDRA)
- Clinical data output (CDISC ODM compliance)
- Power analysis and sample size evaluations
- Biostatistical evaluations
- Statistical report writing

Some of OCT clients

Adherex

Bayer

Berlin Chemie

Boehringer Ingelheim

Egis

Ferring Pharmaceuticals International

Geropharm

GSK

Hospira UK Limited

Incuron

KRKA

Menarini International

MYR GmbH/Hepatera

Novartis

Oasmia Pharmaceutical AB

Oncopeptides AB

Onyx Pharmaceuticals, Inc

Pfizer European Service Center

Pharma Bio

Pharmsynthez

Reckitt Benckiser


R-Pharm

Senju

Sinclair Pharmaceuticals

SynBio

Overall Indexed Clinical Trial Costs



Source: A.T. Kearny analysis

Contact



Russia

HEADQUARTERS:

8/2 Bolshaya Moskovskaya Str., Suite 4-1
St.Petersburg, 191002, Russia

MOSCOW OFFICE:

Gamsonovsky per. 2, building 2, Suite 77-82,
Moscow 115191, Russia



USA BD Office

845 Third Avenue, 6th Floor
New York, NY 10022, US



Ukraine

34 Lesi Ukrainki Str., Suite 219
PO box 50, 01601, Kiev, Ukraine



Bulgaria

Sofia, district Triaditza, 53, Tzarigradsko Shosse,
Blvd., bl. 2, floor 1, Apt. 4



The Baltic States



Bauskas str. 33-4



Riga, LV-1004, Latvia



Belarus

Severnny per. 13/2, Suite 3
Minsk, 220036, Belarus

Our Advantage is our
Commitment to Excellence



Full-service clinical trials in Central and Eastern Europe

Thank you for your attention